Quick Answer
Immunocore Holdings plc reported Stockholders Equity of $381.03 million for the year ending 2025.
- Immunocore Holdings plc showed an increase of +5.6% in Stockholders Equity from 2024 to 2025.
- This data is from Immunocore Holdings plc's annual report (Form 10-K), filed with the SEC on February 25, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2023: $341.30 million | Q2 2023: $351.44 million | Q3 2023: $355.97 million | Q1 2024: $359.53 million | Q2 2024: $359.14 million | Q3 2024: $377.83 million | Q1 2025: $378.48 million | Q2 2025: $388.48 million | Q3 2025: $396.56 million.
- Over the full 6 years of available data (2020 to 2025), Immunocore Holdings plc's Stockholders Equity has grown by 395.4%.
- Historical annual values: Fiscal year 2025: $381.03 million | Fiscal year 2024: $360.72 million | Fiscal year 2023: $368.84 million | Fiscal year 2022: $338.90 million | Fiscal year 2021: $233.71 million | Fiscal year 2020: $76.91 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: